What is Theratechnologies Inc (THTX)?

Theratechnologies Inc (THTX) Stock Analysis

$3.390

0.000 (0.00%)At close

Loading chart…

High: 3.400
Open: 3.360
VWAP: 3.38
Vol: 3.27M
Mkt Cap: 63.91M
Low: 3.340
Amount: 11.05M
EV/EBITDA, TTM: 5.08

Theratechnologies Inc. is a Canada-based specialty biopharmaceutical company focused on the commercialization of innovative therapies. The Company offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. It markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The Company is also focusing on tesamorelin life-cycle management in lipodystrophy.

Valuation Metrics

The current forward P/E ratio for Theratechnologies Inc (THTX) is 22.64, compared to its 5-year average forward P/E of 15.75.

Forward P/E

Fair

5Y Average P/E

15.75

Current P/E

22.64

Overvalued

59.02

Undervalued

-27.51

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

110.69

Current EV/EBITDA

5.08

Overvalued

424.91

Undervalued

-203.52

Forward P/S

Fair

5Y Average P/S

1.53

Current P/S

0.77

Overvalued

2.54

Undervalued

0.52

Alphio AI Price Scenarios for THTX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%THTX

$3.26

Scenario price

Base

Base · 50%THTX

$2.67

Scenario price

Bear

Bear · 25%THTX

$2.31

Scenario price

Events Timeline

2025-09-05 (ET)